Glucagon-like peptide-1 agonists may be safe for patients with diabetes undergoing THA
Click Here to Manage Email Alerts
Key takeaways:
- Glucagon-like peptide-1 agonists were not associated with complications for patients with diabetes who underwent hip arthroplasty.
- Glucagon-like peptide-1 agonists were associated with shorter length of stay.
According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.
Results showed glucagon-like peptide-1 (GLP-1) agonists may be associated with decreased rates of extended hospital stays after THA.
Kevin Y. Heo, BS, fourth-year medical student in the department of orthopedic surgery at Emory University School of Medicine, and colleagues retrospectively analyzed data from 14,065 patients with type 2 diabetes who underwent unilateral THA between January 2016 and December 2021.
Among the cohort, 812 patients used GLP-1 agonists within 6 months preoperatively, while 10,884 patients did not use GLP-1 agonists within 6 months preoperatively.
After matching patients for age, sex, insulin status, other diabetic medications, comorbidities and smoking status, Heo and colleagues performed a final analysis of 812 patients who used GLP-1 agonists and 3,248 patients who did not use GLP-1 agonists.
Overall, Heo and colleagues found no significant differences between the groups for 90-day rates of complications or 1-year rates of all-cause revision, aseptic revision or periprosthetic joint infection. They also found patients who did not use GLP-1 agonists had increased risks for hospital stays of 3 days or more compared with patients who used GLP-1 agonists (OR = 1.25).
“This provides important information given the increasing popularity of these medications among the general and arthroplasty populations,” Heo and colleagues wrote in the study. “Given the potential for increased glycemic control and weight loss, more data is needed to delineate the role of GLP-1 agonists in the optimization of patients who have diabetes before THA to minimize postoperative complications.”
Collapse
Click Here to Manage Email Alerts